Biogen (BIIB) Income from Continuing Operations (2009 - 2026)

Biogen (BIIB) has reported Income from Continuing Operations for 18 consecutive years, with 319500000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 32.85% year-over-year to 319500000.0; the TTM figure through Mar 2026 stood at 1371900000.0 (down 7.26% YoY), while the FY2025 annual figure was 1292900000.0, down 20.79% from the prior year.
• Income from Continuing Operations came in at 319500000.0 for Q1 2026 at Biogen, up from 48900000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 1134900000.0 in Q3 2022, with the low at 68300000.0 in Q3 2023.
• Average Income from Continuing Operations over 5 years is 433241176.47, with a median of 388500000.0 recorded in 2024.
• Across the five-year window, Income from Continuing Operations surged 1538.48% in 2022 and plunged 118.34% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 549500000.0 in 2022, then plunged by 54.7% to 248900000.0 in 2023, then increased by 7.15% to 266700000.0 in 2024, then slumped by 118.34% to 48900000.0 in 2025, then surged by 753.37% to 319500000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 319500000.0, 48900000.0, and 466500000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.